JNJ

235.08

+0.29%↑

ISRG

479.97

+0.14%↑

ABT

109.21

+0.48%↑

RDY

14.03

+1.74%↑

NEOG

10.37

+0.97%↑

JNJ

235.08

+0.29%↑

ISRG

479.97

+0.14%↑

ABT

109.21

+0.48%↑

RDY

14.03

+1.74%↑

NEOG

10.37

+0.97%↑

JNJ

235.08

+0.29%↑

ISRG

479.97

+0.14%↑

ABT

109.21

+0.48%↑

RDY

14.03

+1.74%↑

NEOG

10.37

+0.97%↑

JNJ

235.08

+0.29%↑

ISRG

479.97

+0.14%↑

ABT

109.21

+0.48%↑

RDY

14.03

+1.74%↑

NEOG

10.37

+0.97%↑

JNJ

235.08

+0.29%↑

ISRG

479.97

+0.14%↑

ABT

109.21

+0.48%↑

RDY

14.03

+1.74%↑

NEOG

10.37

+0.97%↑

Home・Akciju saraksts・Microbot Medical Inc

Microbot Medical Inc

Atvērts

1.76 -0.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.71

Max

1.81

Galvenie mērījumi
By Trading Economics
Ienākumi	-77K -3.6M
Darbinieki	20
EBITDA	-79K -3.6M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+386.11% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 23. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-21M 120M
Iepriekšējā atvēršanas cena	2.32
Iepriekšējā slēgšanas cena	1.76

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

2.52 / 2.57 Atbalsts un pretestība

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. febr. 23:11 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026. g. 3. febr. 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. febr. 23:50 UTC

Tirgus saruna

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026. g. 3. febr. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026. g. 3. febr. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026. g. 3. febr. 23:38 UTC

Peļņas

AMD Sales Climb on Help From Data-Center Business -- Update

2026. g. 3. febr. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026. g. 3. febr. 23:27 UTC

Iegādes, apvienošanās, pārņemšana

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026. g. 3. febr. 23:25 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026. g. 3. febr. 23:23 UTC

Iegādes, apvienošanās, pārņemšana

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026. g. 3. febr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026. g. 3. febr. 23:19 UTC

Tirgus saruna

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026. g. 3. febr. 23:19 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. febr. 22:56 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026. g. 3. febr. 22:40 UTC

Peļņas

Amdocs Extends Collaboration With T-Mobile

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q Adj EPS $1.81

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q Rev $1.16B

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q EPS $1.45 >

2026. g. 3. febr. 22:38 UTC

Peļņas

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026. g. 3. febr. 22:30 UTC

Iegādes, apvienošanās, pārņemšana

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026. g. 3. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026. g. 3. febr. 22:14 UTC

Peļņas

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026. g. 3. febr. 22:13 UTC

Peļņas

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026. g. 3. febr. 22:12 UTC

Peļņas

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026. g. 3. febr. 22:10 UTC

Peļņas

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026. g. 3. febr. 22:10 UTC

Peļņas

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026. g. 3. febr. 22:10 UTC

Tirgus saruna

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026. g. 3. febr. 22:10 UTC

Peļņas

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026. g. 3. febr. 22:09 UTC

Peļņas

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026. g. 3. febr. 22:09 UTC

Peļņas

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

386.11% augšup

Prognoze 12 mēnešiem

Vidējais 8.75 USD 386.11%

Augstākais 12 USD

Zemākais 5.5 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.